Fig. 1. Differential change from baseline to week 12 in depression-anxiety symptoms, severity, global experience, functioning and quality of life scores according to treatment group (minocycline/placebo) and illness chronicity, systemic illness, and adverse effects.
Scale ranges: MADRS (0−60), HAMD (0−52), Q-LES-Q (14−70), LIFE-RIFT (4−20), SOFAS (0−100), PGI (1−7), CGI-S (1−7), CGI-I (1−7). Positive change is indicative of favorable results for every scale in the graph. In all clinical scales, higher scores indicate worse outcomes, except for Q-LES-Q and SOFAS. Therefore the latter were inverted. Changes in PGI and CGI-I were evaluated between week 2 and week 12.
BMI, body mass index; CGI-S, Clinical Global Impression-Severity; CGI-I, Clinical Global Impression-Improvement; HAM-A, Anxiety symptoms were assessed with the Hamilton Anxiety Rating Scale; LIFE-RIFT, Range of Impairment Functioning Tool; MADRS, Montgomery–Asberg Rating Scale; PGI, Patient Global Impression; Q-LES-Q, Quality of Life Enjoyment and Satisfaction Questionnaire; SOFAS, Social and Occupational Functioning Assessment Scale.
© Clin Psychopharmacol Neurosci